Vasily Mamonov - Concepedia

Concepedia

Author

Vasily Mamonov

National Medical Research Center for Hematology ORCID

Also Known As

V E Mamonov, V. E Mamonov, V. E. Mamonov, V. MAMONOV, V. Mamonov, Vasily E Mamonov, Vasily E. Mamonov, Vasily Mamonov

31

Publications

1.1K

Citations

10

H-Index

16

Concepts

All Affiliations

National Medical Research Center for Hematology Baxter (United States)University Hospital St. Marina Baikov Institute of Metallurgy and Materials Science Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine

VM

About

Vasily Mamonov is an author at National Medical Research Center for Hematology specializing in medicine, engineering, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	363
2	Engineering	2	2	115
3	Biomedical Engineering	2	2	115
4	Biochemistry	1	1	101
5	Health Policy	1	1	252

Vasily Mamonov

×

11

Publications

1.1K

Citations

10

H-Index

	Year	Citations
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy John Pasi, Savita Rangarajan, Pencho Georgiev, New England Journal of Medicine	2017	345
A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management Leonard A. Valentino, Vasily Mamonov, Andrzej Hellmann, Journal of Thrombosis and Haemostasis Prophylaxis TreatmentsHealth PolicyHematologyPaired ComparisonMedicine	2011	252
Randomized comparison of prophylaxis and on‐demand regimens with <scp>FEIBA NF</scp> in the treatment of haemophilia A and B with inhibitors Sandra Vallin Antunes, Srilatha Tangada, Oleksandra Stasyshyn, Haemophilia	2013	112
Bioceramics Composed of Octacalcium Phosphate Demonstrate Enhanced Biological Behavior I. Y Bozo, R. V Deev, I. I Eremin, ACS Applied Materials & Interfaces Tissue EngineeringEngineeringBone RepairBiomedical EngineeringOsteoporosis	2014	101
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort John Pasi, Toshko Lissitchkov, Vasily Mamonov, Journal of Thrombosis and Haemostasis	2021	93
Fibrinogen-modified sodium alginate as a scaffold material for skin tissue engineering E. V. Solovieva, A. Yu. Fedotov, Vasily Mamonov, Biomedical Materials	2017	60
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn, Haemophilia	2013	48
Efficacy and safety of a recombinant factor <scp>IX</scp> (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase <scp>III</scp> study Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn, Haemophilia	2014	26
Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from <scp>FEIBA NF</scp> Prophylaxis Study Oleksandra Stasyshyn, Sandra Vallin Antunes, Vasily Mamonov, Haemophilia	2014	24
Octacalcium phosphate coating for 3D printed cranioplastic porous titanium implants R. V Deev, I. Y Bozo, A. Yu. Fedotov, Surface and Coatings Technology Materials ScienceEngineeringBioceramicBiomedical EngineeringOctacalcium Phosphate Coating	2019	14

Page 1